HIV Clinical Trial
Official title:
A Double-Blind, Single Center, Randomized 3-way Crossover Trial to Determine Pleasure for Fitted, Thin and Standard Condoms, and to Assess Clinical Failure for Vaginal and Anal Sex
This study will enroll 252 men who have sex with men (MSM) and 252 men who have sex with
women (MSW) in a double-blind, three-way randomized crossover trial with conditions of
fitted, thin, and standard condoms. The study will provide fitted condoms in 56 sizes based
on combinations of length (approximately 10 mm increments) and circumference (approximately 2
mm increments), with user-determined size based on a paper template measurement instrument.
Participants will be randomly assigned to the sequence in which the crossover intervention
conditions (fitted, thin, and standard condoms) occur, with five study condoms provided for
each condition. Participants will attend at least four, and up to seven, biweekly study
visits.
Study objectives are to establish label indications for pleasure and patient preference for
fitted condoms, establish label indication for anal sex for fitted, thin, and standard
condoms, and establish a label indication for decreased clinical failure of fitted condoms
for anal sex.
The study will enroll 252 MSM and 252 men who sex with women (MSW) into a double-blind,
three-way randomized crossover trial with conditions of fitted, thin, and standard condoms.
For MSM enrolled in the trial we will assess outcomes based on anal sex, and for MSW we will
assess outcomes based on vaginal sex. The study will provide fitted condoms in 56 sizes based
on combinations of length (approximately 10 mm increments) and circumference (approximately 2
mm increments), with user-determined size based on a paper template measurement instrument.
For purposes of this study, a "standard" condom is defined by dimensions commonly sourced by
the United Nations Population Fund (UNFPA) and United States Agency for International
Development (USAID), which procures the majority of the world's condoms. These dimensions are
185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. "Thin" condoms for
this study will be of identical width and length to "standard", but 50 microns ± 5 microns
thick. Fitted condoms will be produced in a range of sizes with thickness of 70 microns ± 10
microns, with a participant's fitted size as determined by their use of a fitting system
consisting of a paper template graduated with non-sequential numbering and lettering. Condoms
will be manufactured using the same latex formulation and silicone lubricants (approximately
400mg per condom), and with similar parallel wall designs.
Every participant in the trial will receive a set of five fitted condoms (fitted condition),
a set of five thin condoms (thin condition), and a set of five standard condoms (standard
condition) over a series of study visits. Event-level data based on a home coital log will be
collected regarding pleasure and total clinical failure, and data regarding overall condom
preference will be collected at the final study visit. Participants will be randomly assigned
to the sequence in which the crossover intervention conditions (fitted, thin, and standard)
occur. Each participant will attend at least four, and up to seven, biweekly study visits.
Participants will be given up to four weeks to use each study condom set; after 4 weeks with
a set of condoms, participants will be automatically crossed over into the next study
condition. If all condoms are used within the first two weeks, participants will crossover to
the next randomized condition.
Participants will be blinded, with all condoms produced in plain foils with two-digit
identifying codes, and role-based blinding will be conducted for study staff with the
statistician and PI blinded. Participants will be trained in appropriate condom use, fitted
condom sizing, study instructions such as only using study lubricant, and daily coital log
completion. Participants will complete mobile-optimized, web-based home coital logs as soon
as possible following any vaginal or anal sex acts. To assist participants in timely
completion, there will be a daily check-in through Short Message Service (SMS) (via text
message) with a reminder initiated if no sexual event has been recently reported. The coital
log will include outcome measures for pleasure and for condom failure. The final visit survey
will measure overall condom preference.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |